Equities research analysts expect Jazz Pharmaceuticals (NASDAQ:JAZZ) to announce earnings per share (EPS) of $2.73 for the current quarter, Zacks reports. Nine analysts have made estimates for Jazz Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $2.30 and the highest estimate coming in at $2.92. Jazz Pharmaceuticals posted earnings per share of $2.31 during the same quarter last year, which suggests a positive year over year growth rate of 18.2%. The business is scheduled to announce its next earnings results on Tuesday, May 8th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year earnings of $13.04 per share for the current fiscal year, with EPS estimates ranging from $12.91 to $13.15. For the next year, analysts anticipate that the business will post earnings of $15.18 per share, with EPS estimates ranging from $14.42 to $16.04. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. The firm had revenue of $436.40 million for the quarter, compared to the consensus estimate of $440.91 million.
A number of equities analysts recently weighed in on JAZZ shares. Wells Fargo reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. B. Riley reaffirmed a “buy” rating and issued a $206.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 20th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Sunday, December 10th. Piper Jaffray reaffirmed a “buy” rating and issued a $201.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. Finally, Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $180.78.
NASDAQ JAZZ traded down $2.70 during mid-day trading on Friday, reaching $149.91. 475,813 shares of the stock were exchanged, compared to its average volume of 426,519. Jazz Pharmaceuticals has a one year low of $128.58 and a one year high of $163.75. The company has a market capitalization of $8,965.07, a PE ratio of 15.68, a P/E/G ratio of 0.78 and a beta of 0.97. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.57.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $150.01, for a total value of $150,010.00. Following the transaction, the chief executive officer now directly owns 293,542 shares in the company, valued at $44,034,235.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $152.16, for a total transaction of $106,512.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,758 shares of company stock worth $2,031,181. 4.30% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE raised its position in shares of Jazz Pharmaceuticals by 49.5% in the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after purchasing an additional 360 shares during the period. We Are One Seven LLC bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $157,000. Invictus RG bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $206,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in Jazz Pharmaceuticals by 795.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 1,551 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 91.20% of the company’s stock.
WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/analysts-expect-jazz-pharmaceuticals-jazz-to-post-2-73-eps.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.